Autoantibody against a protease domain of caspase-8 in patients with systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 26, Issue 6, 2008, Pages 998-1004

  Yamaoka, Toshifumi ^a   Ogawa, Fumihide ^a   Muroi, Eiji ^a   Hara, Toshihide ^a   Komura, Kazuhiro ^a   Iwata, Yohei ^a   Takenaka, Motoi ^a   Shimizu, Kazuhiro ^a   Hasegawa, Minoru ^b   Fujimoto, Manabu ^b   Sato, Shinichi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Autoantibody; Caspase 8; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; CASPASE 8; ENZYME ANTIBODY; PROTEINASE; RECOMBINANT ENZYME;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBSTRATE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOBLOTTING; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; SCLERODERMA; SEROLOGY; SPECTROPHOTOMETRY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ADULT; AGED; AUTOANTIBODIES; AUTOIMMUNITY; CASPASE 8; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PROTEIN STRUCTURE, TERTIARY; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 59149085881     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. OKANO Y: Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996; 22: 709-35.
2. IWATA Y, OGAWA F, KOMURA KM et al.: Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: Possible association with oxidative stress. Rheumatology 2007; 46: 790-95.
3. NISHIJIMA C, HAYAKAWA I, MATSUSHITA T et al.: Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 2004; 138: 357-63.
4. SATO S, HAYAKAWA I, HASEGAWA M et al.: Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003; 120: 542-47.
5. BOATRIGHT KM, SALVESEN GS: Mechanisms of caspase activation. Curr Opin Cell Biol 2003; 15: 725-31.
6. NADIRI A, WOLINSKI MKK SALEH M: The inflammatory caspases: key players in the host response to pathogenic invasion and sepsis. J Immunol 2006; 177: 4239-45.
7. DONEPUDI M, MACSWEENEY A, BRIAND C et al.: Insights into the regulatory mechanism for caspase-8 activation. Mol Cell 2003; 11: 543-9.
8. LIADIS N, SALMENA L, KWAN E et al.: Distinct in vivo roles of Caspase-8 in beta cells in physiological and diabetes models. Diabetes 2007.
9. SALMENA L, HAKEM R: Caspase-8 deficiency in T cells leads to a lethal lymphoinfiltrative immune disorder. J Exp Med 2005; 202: 727-32.
10. STUPACK DG, TEITZ T, POTTER MD et al.: Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 2006; 439: 95-9.
11. UEKI A, ISOZAKI Y, TOMOKUNI A et al.: Intramolecular epitope spreading among anticaspase-8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals. Clin Exp Immunol 2002; 129: 556-61.
12. COMMITTEE SFSCOTARADATC: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
13. LEROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-05.
14. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
15. BOHAN A, PETER JB: Polymyositis and dermatomyositis (first of two parts). N Eng J Med 1975; 292: 344-8.
16. BOHAN A, PETER JB: Polymyositis and dermatomyositis (second of two parts). N Eng J Med 1975; 292: 403-7.
17. CLEMENTS PJ, LACHENBRUCH PA, SEIBOLD JR et al.: Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892-6.
18. SATO S, IHN H, KIKUCHI K et al.: Antihistone antibodies in systemic sclerosis: Association with pulmonary fibrosis. Arthritis Rheum 1994; 37: 391-4.
19. SATO S, IHN H, SOMA Y et al.: Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 1993; 36: 1137-41.
20. CASIANO CA, MARTtN SJ, GREEN DR et al.: Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 1996; 184: 765-70.
21. SGONC R, GRUSCHWITZ MS, DIETRICH H et al.: Endothelial cell apoptosis is a primary pathngeneic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98: 785-92.
22. SUEMATSU M, WAKABAYASHI Y, ISHIMURA Y: Gaseous monoxides: a new class of microvascular regulator in the liver. Cardiovasc Res 1996; 32: 679-86.
23. BUTLER AR, FLITNEY FW, WILLIAMS DL: NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: A chemist's perspective. Trends Pharmacol Sci 1995; 16: 18-22.
24. ROSEN A, CASCIOLA-ROSEN L: Autoantigens as substrates for apoptotic proteases: Implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999; 6: 6-12.
25. BLANCHARD H, DONEPUDI M, TSCHOPP M et al.: Caspase-8 specificity probed at subsite S(4): Crystal structure of the caspase-8-Z-DEVD-cho complex. J Mol Biol 2000; 302: 9-16.
26. WATT W, KOEPLINGER KA, MILDNER AM et al.: The atomic-resolution structure of human caspase-8, a key activator of apoptosis. Structure 1999; 7: 1135-43.
27. MATSUDA N, TAKANO Y, KAGEYAMA SI et al.: Silencing of caspase-8 and caspase-3 by RNA interference prevents vascular endothelial cell injury in mice with endotoxic shock. Cardiovasc Res 2007.